[ad_1]
Team San Sanfilippo Foundation representatives told Proactive Investors that the non-profit medical research foundation has awarded a grant for the upcoming New York-based biotech clinical trial Seelos Therapeutics Inc. (NASDAQ: SEEL) for treatment Sanfillipo syndrome.
Danielle O. Connor, Treasurer of the San Filippo Foundation, along with President Kathleen Buckley and Vice President Patricia Taormino, announced that the NPO would fund Seelos, which will begin the initial dosing for the patient with his treatment SLS-005 in the third quarter of 2019.
Source link
